This week, the United States J. P. At the Morgan Conference, Johnson & Johnson, Pfizer, Eli Lilly, GSK, Bayer, Shinki, Sanofi and many other large global pharmaceutical companies and initial innovations summarized the work in 2017, and made a forward-looking view in 2018; domestic Hengrui, first The sound and the Baekje Shenzhou are non-stop, and a new round of cooperation has begun.
Global wind direction
Johnson & Johnson's R&D field is about to launch 15 new transactions
Recently, Johnson & Johnson announced that it will reach a cooperation agreement with 15 different organizations and companies this year to address unmet medical needs in neuroscience, oncology and other fields.
There are 4 collaborations in the field of neuroscience: including the University of Pennsylvania (Alzheimer's disease), NCICRE (brain health), Holobiome (insomnia), WinterLight laboratory (neurodegenerative disease); 3 collaborations in the field of oncology, including Hehe Comprehensive Cancer Institute (Lung Cancer), Queensland University of Technology (Laryngeal Cancer), MiRXES Pte Ltd (Lung Cancer). The other seven collaborations are involved in dermatological treatment, vision correction, and obesity treatment.
Pfizer's goal for the next five years: launch 15 potential heavy drugs
Between 2005 and 2016, Pfizer launched seven heavyweight products: cancer drug Sutent, Prevnar 13 pneumococcal vaccine, pneumococcal vaccine Prevnar 13, blood thinner Eliquis, rheumatoid arthritis drug Xeljanz, breast cancer drug Ibrance And the drug Eucrisa for the treatment of eczema. Among them, Prevnar 13 pneumococcal vaccine sales of about 5.4 billion US dollars in 2017, it is Pfizer's best-selling product. Ibrance is one of Pfizer's fastest growing stars.
Mikael Dolsten, president of Pfizer Global R&D, said that in the next five years, Pfizer hopes to launch as many as 15 potential heavy drugs. Five of them may be in the field of cancer. They include new indications for Ibrance and Xtandi, as well as a combination of Pfizer 's Bavencio with the German-made Merck KGaA.
Lilly: $10 billion in cash withdrawals, focusing on the line of cancer treatment products
The change in the law signed by US President Trump in December, the global tax rate for Eli Lilly and Company in Indianapolis will be slightly reduced. Therefore, Lilly will receive a huge amount of cash and will have $10 billion in overseas funds.
“Next, we can invest in building factories and building laboratories without worrying about tax rates. The only problem we need to worry about is talent and the market,†said Lilly CEO David Ricks. At the same time, Ricks also said that he still wants to build a more comprehensive product line, especially in cancer treatment. He said that many competitive companies are now developing immunology, diabetes and oncology treatment businesses.
New Base spends $7 billion to buy ImpactBiomedicines
On the first day of the Morgan Conference, the news of the acquisition of ImpactBiomedicines by Celgene was introduced. Xinji said it is determined to acquire ImpactBiomedicines and will pay a down payment of US$1.1 billion, which may amount to US$7 billion.
This news detonated the JPM venue! Because ImpactBiomedicines is a very small start-up company, it only completed the $22 million Series A financing three months ago (and later about $90 million in additional financing), all for the development of Sanofi. Abandoned the drug JAK2 inhibitor Fedratinib (SAR302503, TG101348). According to analysis, the acquisition is a drug candidate for the treatment of blood cancer, because it is expected to become a strong competitor of Novartis heavy drug Jakafi (the first drug to treat myelofibrosis).
Breaking up rumors! Sanofi & Regeneration Yuan announced expansion of investment
SanofiSA and Regeneron, which are rumored to break up, announced at the Morgan Conference that they will expand their investments in immuno-oncology and allergic diseases.
At present, Regeneration and Sanofi have three FDA-approved drugs, namely Praluent (anti-PCSK9), Dupixent (anti-IL-4R) and Kevzara (anti-IL-6R). Next, the two sides will further expand their investment in Dupixent's indications, especially in the area of ​​allergic reactions.
At the same time, Regeneration and Sanofi will invest another $1 billion for the promotion of cemiplimab. Cemiplimab is an immunological checkpoint inhibitor for PD-1 developed by Sanofi and Regeneration Corporation.
GSK: Does not rule out the possibility of acquiring Pfizer's consumer health department
Glaxo Smith Kline CEO Emma Walmsley said: "We need to make some changes to achieve even stronger growth after 2020, especially in our most competitive pharmaceutical industry."
Since becoming CEO in April 2017, Walmsley has been strengthening the pharmaceutical product line, focusing on new and less refined drugs, which is her goal.
Walmsley said, "The pharmaceutical industry, especially in consumer health and vaccines, is our top priority." But it does not rule out the possibility of GSK's acquisition of the consumer health sector that Pfizer plans to divest. However, he also stressed that it is still in the preliminary observation stage and will not pay high prices to facilitate the transaction.
Bayer: Leaps project invests $575 million in five years
In 2017, Bayer used the “Leaps†project to find solutions to the top ten challenges facing humanity and established three new companies to capture disruptive technologies and breakthrough innovations.
Carsten Brunn, head of Bayer's US pharmaceutical company, said the project hopes to provide treatment for health and food supply problems caused by aging and population growth. In the pharmaceutical sector, Bayer will focus on six major disease areas, including blood diseases, blindness and heart disease. The Leaps project will invest $575 million over five years to provide a strategic direction for the company.
Some overseas companies focus on product summary
(The contents of the table are organized from WuXi PharmaTech's article "JPM Report: What are the dynamics of biopharmaceutical companies in 2018?")
Dietary supplements take vitamins, minerals and extracts with relatively clear structure-activity relationship as the main raw materials, and supplement the necessary nutrients and biologically active substances for the human body through oral intake to achieve the purpose of improving the body's health and reducing the risk of disease. Available in concentrated forms such as doses or capsules. Foods in traditional form with added nutrients or biologically active substances.
Dietary supplement,New Dietary Ingredient,Dietary Supplement Product,Food Supplements
YT(Xi'an) Biochem Co., Ltd. , https://www.ytherblifes.com